Tajima, C. (1984). Tamoxifen in the treatment of infertile patients associated with inadequate luteal phase. Fertility and Sterility, 41(3), 470-472. https://doi.org/10.1016/s0015-0282(16)47730-7
Tajima C. Tamoxifen in the treatment of infertile patients associated with inadequate luteal phase. Fertil Steril. 1984;41(3):470-472. doi:10.1016/s0015-0282(16)47730-7
Tajima, Choshin. "Tamoxifen in the treatment of infertile patients associated with inadequate luteal phase." Fertility and Sterility, vol. 41, no. 3, 1984, pp. 470-472.
For EndNote, Zotero or Mendeley:
Open access
Free to read
No reuse license
Free to read at the publisher (reported by Unpaywall and OpenAlex, not verified by RRM Academy)
Tamoxifen Raises Low Progesterone In Women With Weak Luteal Phases
This 1984 study followed 12 infertile women with a weak luteal phase. Each woman acted as her own control, before and after treatment. Progesterone after ovulation rose after a short course of tamoxifen. The rise was biggest in the six women who started lowest. Five normal cycling women gave a reference range.
Study at a glance, Each woman acted as her own control of 12 infertile women: Tamoxifen raised low progesterone in women with weak luteal phases. Source: Tajima C, 1984, PMID 6421628.
Key Findings
The 12 women were split into two groups of six based on their starting progesterone level.
In the six women with the lowest starting level, progesterone after ovulation rose significantly after tamoxifen (p<0.001).
In the six women who started with higher progesterone, tamoxifen produced a smaller but still significant rise (p<0.05).
Progesterone did not change significantly in the one normally cycling volunteer who took tamoxifen.
Follicular-phase FSH and LH were reported for one woman per group (one from each patient group and one normal woman). Neither differed significantly between treated and untreated cycles.
Interpretation
This 1984 trial followed 12 women. Each woman was her own control: one untreated cycle, one tamoxifen cycle. Progesterone after ovulation rose with tamoxifen. The rise was biggest in the six women who started lowest. Five normally cycling women gave a reference range. The findings support larger studies of tamoxifen's effect on luteal-phase progesterone.
RRM Context
Restorative reproductive medicine looks for a weak luteal phase through cycle-timed hormone testing. This 1984 paper is an early example of that approach. The authors tie hormone tests to a woman's own cycle, then check whether a drug changes the pattern. The finding belongs to this one trial. NaProTechnology and Creighton Model are named methods with their own protocols for luteal-phase support, and RRM-trained clinicians handle luteal-phase findings in different ways.
Our editorial summary of this paper, not the article's abstract.
02cgss904 
